Cite

HARVARD Citation

    Rajan, A. et al. (2019). Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. Journal for immunotherapy of cancer. 7 (1), p. . [Online]. 
  
Back to record